EUVIMEDEUVIMED entdecken
Crossref

Experience with rituximab in complex therapy of adult patients with common variable immunedeficiency with symptoms of immune dysregulation

Nailya Kh. Setdikova, Tatiana S. Romanova, Evgeniy A. Frolov, Tatyana V. Latysheva, Tatiana N. Myasnikova, Yuliya M. Klimanova, Nikolay A. Nazarov, Gulumkhan E. Aminova, Elena A. Latysheva

Russian Journal of Allergy · 16.04.2026 · 23 (2) · 137-149

DOI: 10.36691/rja17082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Allergy, online erschienen am 16.04.2026. Verfasst von Nailya Kh. Setdikova und 8 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Due to the successful use of immunoglobulins, non-infectious complications have become the main cause of disability and mortality in patients with primary immunodeficiencies, necessitating the development of treatment protocols for complications of immune dysregulation. The development of lymphocytic infiltration of organs, granulomatous disease, autoimmune manifestations, and cancer exacerbates the course of the underlying disease and determines the patient’s life prognosis. Rituximab is one of the most commonly used medications. No large randomized controlled studies have been conducted on the use of rituximab in patients with common variable immune deficiency with signs of immune dysregulation. AIM: Evaluation of the effectiveness of rituximab therapy for the treatment of immune dysregulation complications in patients with common variable immune deficiency over the age of 18. METHODS: The study included 31 patients aged 19 to 62 years with a general variable immune deficiency, manifested by symptoms of immune dysregulation without an identified molecular genetic defect. Rituximab was included in the complex therapy of the disease for all patients. RESULTS: 31 case histories of patients with common variable immune deficiency aged 19 to 62 years were analyzed. The average age of the total sample was 38.13 ± 2.20 years. Of these, 18 (58.06 %) were women and 13 (41.94 %) were men. All patients showed symptoms of immune dysregulation: granulomatous-lymphocytic interstitial lung disease in 28 (90.32 %) patients, including 16 (88.88 %) women and 12 (92.30 %) men. Splenomegaly was observed in 26 (83.87%) of all patients. Splenectomy was performed in 5 (16.13 %) patients (all patients were male). Lymphadenopathy in 30 (96.77 %) patients, 12 (92.31 %) men and 18 (100 %) women. Thrombocytopenia in 22 (70.97 %) patients, 10 (76.92 %) men and 12 (66.67 %) women. Autoimmune hemolytic anemia in 5 (16.13 %) patients in the total sample, in 3 (23.07 %) men, 2 (11.11 %) women. Еighteen patients (58,06 %) in the anamnesis received other lines of therapy without effect or with a short-term effect. All patients received therapy with rituximab. Treatment regimen: 4-fold administration of rituximab at a dose of 375 mg/m2 at 7-day intervals, followed by 3 administrations every 3 months. After one year of treatment, 89.28 % of patients with granulomatous-lymphocytic interstitial lung disease experienced complete regression of symptoms and changes in instrumental examinations. Additionally, 63.33 % of patients reported a reduction in the size of their spleen and lymph nodes. Normalization of blood parameters (thrombocytopenia) in 59,09 % of patients. No adverse events were observed during the year-long use of rituximab. CONCLUSION: The efficacy and safety of rituximab in adult patients with common variable immune deficiency with immune regulation manifestations have been proven.

Zitieren

APA

Setdikova, N. K., Romanova, T. S., Frolov, E. A., Latysheva, T. V., Myasnikova, T. N., Klimanova, Y. M., Nazarov, N. A., Aminova, G. E., & Latysheva, E. A. (2026). Experience with rituximab in complex therapy of adult patients with common variable immunedeficiency with symptoms of immune dysregulation. Russian Journal of Allergy, 23(2), 137-149. https://doi.org/10.36691/rja17082

Vancouver

Setdikova NK, Romanova TS, Frolov EA, Latysheva TV, Myasnikova TN, Klimanova YM, et al. Experience with rituximab in complex therapy of adult patients with common variable immunedeficiency with symptoms of immune dysregulation. Russian Journal of Allergy. 2026;23(2):137-149. doi:10.36691/rja17082

BibTeX
@article{Setdikova2026,
  author = {Setdikova, Nailya Kh. and Romanova, Tatiana S. and Frolov, Evgeniy A. and Latysheva, Tatyana V. and Myasnikova, Tatiana N. and Klimanova, Yuliya M. and Nazarov, Nikolay A. and Aminova, Gulumkhan E. and Latysheva, Elena A.},
  title = {Experience with rituximab in complex therapy of adult patients with common variable immunedeficiency with symptoms of immune dysregulation},
  journal = {Russian Journal of Allergy},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {137--149},
  doi = {10.36691/rja17082}
}
Kostenlos starten →